Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice

Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the c...

Full description

Bibliographic Details
Main Authors: Aditi P. Singh, Elaine Shum, Lakshmi Rajdev, Haiying Cheng, Sanjay Goel, Roman Perez-Soler, Balazs Halmos
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/5/1156
id doaj-92f77aac00854f7c8a247b42d8cbc4fc
record_format Article
spelling doaj-92f77aac00854f7c8a247b42d8cbc4fc2020-11-25T03:13:19ZengMDPI AGCancers2072-66942020-05-01121156115610.3390/cancers12051156Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical PracticeAditi P. Singh0Elaine Shum1Lakshmi Rajdev2Haiying Cheng3Sanjay Goel4Roman Perez-Soler5Balazs Halmos6Division of Hematology and Oncology, University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA 19104, USADivision of Medical Oncology and Hematology, NYU Langone Perlmutter Cancer Center, New York, NY 10016, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USADepartment of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10467, USAPurpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., <i>EGFR</i>/<i>ALK</i> for non-small cell lung cancer (NSCLC) and extended-<i>RAS</i> for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.https://www.mdpi.com/2072-6694/12/5/1156comprehensive genomic profilingmolecular genotyping
collection DOAJ
language English
format Article
sources DOAJ
author Aditi P. Singh
Elaine Shum
Lakshmi Rajdev
Haiying Cheng
Sanjay Goel
Roman Perez-Soler
Balazs Halmos
spellingShingle Aditi P. Singh
Elaine Shum
Lakshmi Rajdev
Haiying Cheng
Sanjay Goel
Roman Perez-Soler
Balazs Halmos
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Cancers
comprehensive genomic profiling
molecular genotyping
author_facet Aditi P. Singh
Elaine Shum
Lakshmi Rajdev
Haiying Cheng
Sanjay Goel
Roman Perez-Soler
Balazs Halmos
author_sort Aditi P. Singh
title Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
title_short Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
title_full Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
title_fullStr Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
title_full_unstemmed Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
title_sort impact and diagnostic gaps of comprehensive genomic profiling in real-world clinical practice
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-05-01
description Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., <i>EGFR</i>/<i>ALK</i> for non-small cell lung cancer (NSCLC) and extended-<i>RAS</i> for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.
topic comprehensive genomic profiling
molecular genotyping
url https://www.mdpi.com/2072-6694/12/5/1156
work_keys_str_mv AT aditipsingh impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT elaineshum impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT lakshmirajdev impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT haiyingcheng impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT sanjaygoel impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT romanperezsoler impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
AT balazshalmos impactanddiagnosticgapsofcomprehensivegenomicprofilinginrealworldclinicalpractice
_version_ 1724647507677413376